Filing excerpt
Acquired in-process research and development 101.9 12.3
sec.gov/Archives/edgar/data/872589/000087258926000016/regn-20260331.htmRead the full source
Regeneron10-Q: Data investment
Acquired R&D spending surges 8x to $101.9M, signaling new data integration needs.
Source
Other signals in this filing (8)
- Capex increaseRegeneron investing $255.8M in Q1 for facility expansion in US and IrelandCapex increase
- Acquisition announcedRegeneron boosts M&A activity with $101.9M spent on in-process R&D in Q1 2026Acquisition announced
- Capex increaseRegeneron boosts R&D spend by $216M YoY, increasing headcountCapex increase
- Capex increaseRegeneron spends $101.9M in Q1 to acquire new antibody technologyCapex increase
- Litigation materialRegeneron facing securities class action lawsuit diverting management resourcesLitigation material
- Governance changeRegeneron overhauling board structure, phasing out staggered board by 2028Governance change
- Capex increaseRegeneron authorizes new $3.0 billion share repurchase program in April 2026Capex increase
- Board changeBoard of directors will be declassified, with all directors up for annual election by 2028Board change
Extracted by Autobound
From the Signal API record- Signal
- 10-Q: Data investment
What this signalsFilings often name leadership changes, deals and spending plans.
- Fiscal year end
- 03/31
- Filed
- Apr 29, 2026
More from Regeneron
- PatentsRegeneron Pharmaceuticals, Inc's patent output is steady: 168 grants in the past year, 15 in the past 30 days.Patents
- EarningsRegeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026Earnings
- RedditA Clinical Research Coordinator who completed two studies with Regeneron praised the company for having a super responsive, accessible, and cooperative team.Reddit
- In developmentParoxysmal Nocturnal Hemoglobinuria Market Forecast Upto 2036: 5 Emerging Therapies Poised to Accelerate Market GrowthIn development
- GlassdoorEmployees report toxic work life balance and long hours despite good benefitsGlassdoor
- LaunchRegeneron Pharmaceuticals (REGN) Wins FDA Approval For Pasatru In Adult FOPLaunch
More 10-Q signals at other companies
- SEC 10-QMillerKnoll, Inc.Jeffrey M. Stutz appointed Interim Chief Executive Officer.SEC 10-Q
- SEC 10-QCID HoldCo, Inc.Disclosed material weaknesses in financial reporting due to insufficient accounting staff and controls.SEC 10-Q
- SEC 10-QScholastic CorporationCore school channels decline with fewer book fairs and lower club participation.SEC 10-Q
The full record
From the Signal API recordNumbers
- Dollar figure
- $102M (Acquired in-process research and development expense for Q1 2026)
Details
- CIK
- 872589
- Accession number
- 0000872589-26-000016
- Timeframe
- Current quarter
- Filing year
- 2026
- Fiscal year
- 0
- Why it matters
- Target for data vendors
- Signal category
- Technology
Extraction
- Confidence
- Medium
- Relevance
- 80%
- Sentiment
- Neutral
- Detected
- May 5, 2026
- signal_type
sec-10q- signal_subtype
dataInvestment
Use this data
Get every 10-Q signal for Regeneron and the companies you sell to, in the tools you already use.
Ask Claude about it
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Regeneron this week?”
Send it to your own tools
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Try it free
Sign up and spend your free credits on the companies you sell to.
Start Free1,000 free credits
The API returns more than this page shows
This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the API
Signal
signal_nameValue in the APIassociationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONHide the full JSONThe record on this page and the API request
GET /v1/signals/ca9831f7-061e-43a4-babc-b1c43484bb48 returns this record as JSON. POST /v1/companies/enrich returns every signal for regeneron.com.
{
"signal_id": "ca9831f7-061e-43a4-babc-b1c43484bb48",
"signal_type": "sec-10q",
"signal_subtype": "dataInvestment",
"detected_at": "2026-05-05T08:48:22.581+00:00",
"company": {
"name": "Regeneron",
"domain": "regeneron.com"
},
"data": {
"detail": "A more than 8-fold year-over-year increase in spending on acquired in-process R&D implies the onboarding of new assets, which likely creates urgent needs for integrating disparate research datasets, clinical trial information, and scientific platforms.",
"metrics": {
"timeframe": "current_quarter",
"dollar_context": "Acquired in-process research and development expense for Q1 2026",
"dollar_millions": 101.9
},
"summary": "Acquired R&D spending surges 8x to $101.9M, signaling new data integration needs.",
"excerpts": "Acquired in-process research and development 101.9 12.3",
"relevance": 0.8,
"sentiment": "neutral",
"confidence": "medium",
"source_url": "https://www.sec.gov/Archives/edgar/data/872589/000087258926000016/regn-20260331.htm",
"filing_date": "2026-04-29",
"filing_year": 2026,
"fiscal_year": 0,
"fiscal_year_end": "03/31",
"sales_relevance": "Target for data vendors",
"signal_category": "technology"
}
}
curl https://signals.autobound.ai/v1/signals/ca9831f7-061e-43a4-babc-b1c43484bb48 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"regeneron.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.